1 January 2005 in Cardiovascular Research
Cardiac fibroblasts form one of the largest cell populations, in terms of cell numbers, in the heart. They contribute to structural, biochemical, mechanical and electrical properties of the myocardium. Nonetheless, they are often disregarded by in vivo and in vitro studies into cardiac function. This review summarizes our understanding of fibroblast origin and identity, their structural organization and role in myocardial architecture, as well as functional aspects related to cell signalling and electro-mechanical function in the heart.
2 April 2004 in Circulation Research
Cardiomyocytes form a conducting network that is assumed to be electrically isolated from nonmyocytes in vivo. In cell culture, however, cardiac fibroblasts can contribute to the spread of excitation via functional gap junctions with cardiomyocytes. To assess the ability of fibroblasts to form gap junctions in vivo, we combine in situ detection of connexins in rabbit sinoatrial node (a tissue that is particularly rich in fibroblasts) with identification of myocytes and fibroblasts using immunohistochemical labeling and confocal microscopy. We distinguish two spatially distinct fibroblast populations expressing different connexins: fibroblasts surrounded by other fibroblasts preferentially express connexin40, whereas fibroblasts that are intermingled with myocytes largely express connexin45. Functionality of homogeneous and heterogeneous cell coupling was investigated by dye transfer in sinoatrial node tissue explants. These studies reveal spread of Lucifer yellow, predominantly along extended threads of interconnected fibroblasts (probably via connexin40), and occasionally between neighboring fibroblasts and myocytes (probably via connexin45). Our findings show that cardiac fibroblasts form a coupled network of cells, which may be functionally linked to myocytes in rabbit SAN.
24 June 2016 in Nature Reviews Drug Discovery
Fibroblasts have central roles in cardiac homeostasis and in the pathogenic remodelling that occurs during myocardial ischaemia, hypertension and heart failure Progress has been made towards rational approaches and mechanisms for targeting fibroblasts and fibrosis in cardiac disease, including cell therapies and micro RNA-, peptide- and drug-based interventions Nature's own repair mechanisms, which include fibroblast-mediated remodelling, could be exploited to re-engineer cardiac scar tissue for patient benefit Pharmaceutically tractable compositions and delivery systems are among the hurdles that must be overcome before fibroblast-based therapies will contribute to improved cardiac health
1 January 1999 in Progress in Biophysics and Molecular Biology
9 June 2010 in Clinical Pharmacology & Therapeutics